Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Expert Opin Drug Deliv. 2011 Feb 24;8(4):415–433. doi: 10.1517/17425247.2011.559457

Figure 6. A pictorial scheme for cell-based nanoformulated drug delivery.

Figure 6

Three possible ways of BMM-mediated therapeutic effects of catalase nanozyme in PD mouse model: Pathway I: BMM loaded with nanozyme cross the BBB and release catalase in the SNpc; Pathway II: nanozyme is released from BMM to the blood stream and bypasses the BBB independently of cell-carriers; Pathway III: catalase nanozyme released from BMM in the liver and spleen suppresses peripheral leukocyte activation that results in significant protection of nigrostratial neurons against MPTP-induced neurodegeneration. Used with permission 71.